TITLE

Peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections

AUTHOR(S)
Torriani, F.J.
PUB. DATE
January 2005
SOURCE
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. In patients with concurrent HIV and chronic hepatitis C virus infections, peginterferon X-2a plus ribavirin was more effective than peginterferon OC-2a plus placebo, and peginterferon X-2a plus placebo was more effective than interferon OC-2a plus ribavirin for inducing a sustained hepatitis C virologie response.
ACCESSION #
15851777

 

Related Articles

  • Virological response reduces mortality in HIV/hepatitis C coinfection. Levitan, Dave // Infectious Disease News;Apr2008, Vol. 21 Issue 4, p28 

    The article discusses research on the association between sustained virological response (SVR) to interferon plus ribavirin and reduction in liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. It references a study by J. Berenguer et al, presented at...

  • Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon α -- hype or hope? Vogel, Wolfgang // Wiener Klinische Wochenschrift;2004, Vol. 116 Issue 15/16, p508 

    Comments on the response of chronic hepatitis C patients to combination therapy with ribavirin and interferon. Administration of ribavirin and interferon; Prevalence of chronic hepatitis C; Benefits of the combination therapy for patients with chronic C patients.

  • Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Hazari, Sidhartha; Taylor, Lizeth; Haque, Salima; Garry, Robert F.; Florman, Sander; Luftig, Ronald; Regenstein, Frederic; Dash, Srikanta // Virology Journal;2007, Vol. 4, p89 

    Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to...

  • Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment. Jain, Mamta K.; He-Jun Yuan; Adams-Huet, Beverley; Reeck, Amanda; Shelton, Janel; Attar, Nahid; Song Zhang; Neumann, Avidan U.; Carney, David S.; Gale, Jr., Michael; William M. Lee // Journal of Infectious Diseases;9/15/2009, Vol. 200 Issue 6, p866 

    Background. Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection.We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein....

  • Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C. Poordad, Fred; Reddy, K. Rajender; Martin, Paul // Clinical Infectious Diseases;1/1/2008, Vol. 46 Issue 1, p78 

    Background. Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging as an important milestone in the treatment of patients who have chronic hepatitis C by use of pegylated interferon-alfa and ribavirin—the...

  • Therapeutical Aspects and Outcome of HIV/HCV Coinfected Patients Treated with Pegylated Interferon plus Ribavirin in an Italian Cohort. Righi, E.; Beltrame, A.; Bassetti, M.; Lindstrom, V.; Mazzarello, G.; Dentone, C.; Biagio, A.; Ratto, S.; Viscoli, C. // Infection;Aug2008, Vol. 36 Issue 4, p358 

    One-third of HIV-infected individuals suffer from chronic hepatitis C virus infection (HCV) in Europe. Recommendations from HCV–HIV International Panel advise current treatment with pegylated interferon plus ribavirin. We assessed the impact of interferon and ribavirin combination in 43...

  • Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. Fried, Michael W.; Shiffman, Mitchell L.; Reddy, K. Rajender; Smith, Coleman; Marinos, George; Gonçales, Fernando L.; Häussinger, Dieter; Diago, Moises; Carosi, Giampiero; Dhumeaux, Daniel; Craxi, Antonio; Lin, Amy; Hoffman, Joseph; Yu, Jian // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p975 

    Background: Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin,...

  • Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. Schvoerer, Evelyne; Moenne-Loccoz, Rémy; Murray, John M.; Velay, Aurélie; Turek, Marine; Fofana, Isabel; Fafi-Kremer, Samira; Erba, Anne-Claire; Habersetzer, François; Doffoël, Michel; Gut, Jean-Pierre; Donlin, Maureen J.; Tavis, John E.; Zeisel, Mirjam B.; Stoll-Keller, Françoise; Baumert, Thomas F. // Journal of Infectious Diseases;Apr2013, Vol. 207 Issue 8, p1306 

    Background. A major challenge for antiviral treatment of hepatitis C virus (HCV) infection is viral resistance, potentially resulting from the high variability of HCV envelope glycoproteins and subsequent selection of strains with enhanced infectivity and/or immune escape.Methods. We used a...

  • Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation. Panigrahi, Rajesh; Hazari, Sidhartha; Chandra, Sruti; Chandra, Partha K.; Datta, Sibnarayan; Kurt, Ramazan; Cameron, Craig E.; Huang, Zhuhui; Zhang, Haitao; Garry, Robert F.; Balart, Luis A.; Dash, Srikanta // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Purpose:Although chronic hepatitis C virus (HCV) infection has been treated with the combination of interferon alpha (IFN-α) and ribavirin (RBV) for over a decade, the mechanism of antiviral synergy is not well understood. We aimed to determine the synergistic antiviral mechanisms of IFN-α...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics